Information Provided By:
Fly News Breaks for February 20, 2018
BMY, NKTR, ARMO
Feb 20, 2018 | 05:21 EDT
Jefferies analyst Biren Amin started Armo BioSciences (ARMO) with a Buy rating and $61 price target. The analyst thinks the shares will trade on potential for AM0010, an IL-10 cytokine. The data in non-small-cell lung carcinoma show "encouraging signals" and the pancreatic cancer data suggest better activity than chemo alone, Amin tells investors in a research note. He notes cytokines have recently garnered interest after Nektar Therapeutics (NKTR) inked a partnership with Bristol-Myers (BMY) for a $1.8B upfront.
News For ARMO;NKTR;BMY From the Last 2 Days
There are no results for your query ARMO;NKTR;BMY